Literature DB >> 6125395

Binding of beta-adrenoceptor blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to human serum.

F M Belpaire, M G Bogaert, M Rosseneu.   

Abstract

The binding of 8 beta-adrenergic blocking drugs to human serum albumin, to alpha 1-acid glycoprotein and to serum from normal volunteers and from patients with rheumatoid arthritis was studied. Protein binding was determined in vitro using equilibrium dialysis of labelled drug at 25 degrees C. Oxprenolol and propranolol were highly bound to serum, alprenolol, pindolol and timolol to a lesser degree, and atenolol, metoprolol and sotalol were negligibly bound. For the five compounds which were appreciably bound, the mean binding was significantly higher in serum from patients with rheumatoid arthritis than in serum from normal volunteers. For those drugs, binding to alpha 1-acid glycoprotein was higher than to human serum albumin, and binding to a mixture of both proteins approached that to serum from healthy volunteers. For each of these drugs there was a strong correlation between the serum alpha 1-glycoprotein concentration and the percentage binding.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125395     DOI: 10.1007/bf00545224

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Human pharmacokinetics of sotalol.

Authors:  M Anttila; M Arstila; M Pfeffer; R Tikkanen; V Vallinkoski; H Sundquist
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-07

2.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

3.  Binding of two adrenergic beta-receptor antagonists, alprenolol and H 93-26, to human serum proteins.

Authors:  K A Johansson; C Appelgren; K O Borg; R Elofsson
Journal:  Acta Pharm Suec       Date:  1974-09

4.  The distribution of bound propranolol between the different human serum proteins.

Authors:  S Glasson; R Zini; P d'Athis; J P Tillement; J R Boissier
Journal:  Mol Pharmacol       Date:  1980-03       Impact factor: 4.436

5.  The pharmacokinetic characteristics of beta-receptor antagonists in man--similarities and differences of clinical relevance.

Authors:  G W Boyd
Journal:  Aust N Z J Med       Date:  1976-08

Review 6.  Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.

Authors:  G Johnsson; C G Regàrdh
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein.

Authors:  K M Piafsky; O Borgá; I Odar-Cederlöf; C Johansson; F Sjöqvist
Journal:  N Engl J Med       Date:  1978-12-28       Impact factor: 91.245

  7 in total
  26 in total

1.  Drug-disease interactions: reduced beta-adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat.

Authors:  K M Kulmatycki; K Abouchehade; S Sattari; F Jamali
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Pharmacokinetics of intravenously administered 125I-labelled human alpha 1-acid glycoprotein.

Authors:  F Brée; G Houin; J Barré; J L Moretti; V Wirquin; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

3.  The plasma protein binding of basic drugs.

Authors:  P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

4.  Drug binding in the undernourished: a study of the binding of propranolol to alpha 1-acid glycoprotein.

Authors:  V Jagadeesan; K Krishnaswamy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  The relationship between serum concentrations and central nervous system actions of metoprolol.

Authors:  F M Gengo; J C Ermer; C Carey; G C Kalonaros; W B McHugh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-02       Impact factor: 10.154

6.  Influence of continuous ambulatory peritoneal dialysis on serum alpha 1-acid glycoprotein concentration and drug binding.

Authors:  F M Belpaire; E J Van de Velde; N H Fraeyman; M G Bogaert; N Lameire
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  The significance of plasma protein binding on the fetal/maternal distribution of drugs at steady-state.

Authors:  M D Hill; F P Abramson
Journal:  Clin Pharmacokinet       Date:  1988-03       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

9.  A comparison of the pharmacokinetics of atenolol, metoprolol, oxprenolol and propranolol in elderly hypertensive and young healthy subjects.

Authors:  J W Rigby; A K Scott; G M Hawksworth; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

10.  In-vitro relationship between protein-binding and free drug concentrations of a water-soluble selective beta-adrenoreceptor antagonist (atenolol) and its interaction with arsenic.

Authors:  M A Alam; M A Awal; N Subhan; M Mostofa
Journal:  J Health Popul Nutr       Date:  2009-02       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.